NV 105
Alternative Names: Antibody-conjugated Temozolomide liposomal nanoparticle - NanoValent Pharmaceuticals; B7H3/Temozolomide nanoparticles ; NV-105Latest Information Update: 27 Apr 2023
At a glance
- Originator NanoValent Pharmaceuticals
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Carboxylic acids; Drug conjugates; Esters; Immunoconjugates; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 05 Apr 2023 Early research in Glioblastoma in USA (Parenteral) (NanoValent Pharmaceuticals pipeline, April 2023)
- 05 Apr 2023 NanoValent Pharmaceuticals intends to initiate a phase I trial of NV 105 for the treatment of glioblastoma (GBM) (NanoValent Pharmaceuticals pipeline, April 2023)